title: Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?
authors.affiliation: INSERM UMR-S 1124, Université Paris Descartes, UFR Biomédicale des Saints-Pères 45, rue des Saints-Pères, 75270, Paris cedex 06, France, jean.bastin@inserm.fr.
authors.forename: Jean
authors.initials: J
authors.lastname: Bastin
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Bonnefont
authors.forename: Fatima
authors.initials: F
authors.lastname: Djouadi
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Bresson
mesh_terms: D044942:Acyl-CoA Dehydrogenase, Long-Chain / Q000172:deficiency* / Q000235:genetics; D001629:Bezafibrate / Q000009:adverse effects / Q000627:therapeutic use*; D002334:Carnitine O-Palmitoyltransferase / Q000172:deficiency* / Q000235:genetics; D000080984:Congenital Bone Marrow Failure Syndromes; D005227:Fatty Acids / Q000378:metabolism*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008052:Lipid Metabolism, Inborn Errors / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000503:physiopathology; D008066:Lipolysis / Q000187:drug effects*; D008661:Metabolism, Inborn Errors / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000503:physiopathology; D028361:Mitochondrial Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000503:physiopathology; D009135:Muscular Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000503:physiopathology; D010084:Oxidation-Reduction; D016896:Treatment Outcome
chemical_list: D005227:Fatty Acids; D044942:Acyl-CoA Dehydrogenase, Long-Chain; D002334:Carnitine O-Palmitoyltransferase; D001629:Bezafibrate